Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 2/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8307320 | 0.98 | KDM4E (0.61) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL3578797 | 0.83 | KDM4E (0.62) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL9410482 | 0.82 | KDM4E (0.66) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL15209096 | 0.80 | KDM4E (0.59) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL4763456 | 0.78 | MAPT (0.44) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL1889853 | 0.77 | L3MBTL1 (0.43) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL4350886 | 0.77 | KDM4E (0.45) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL8310828 | 0.76 | KDM4E (0.58) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL13982911 | 0.75 | L3MBTL1 (0.42) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL16433570 | 0.75 | L3MBTL1 (0.42) | KDM4ESMN1; SMN2LMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791714-B | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | claimed |
| EP-2552918-B1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | claimed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | claimed |
| EP-2552918-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-06 | — | — | EP | claimed |
| CN-102791714-A | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors | HOFFMANN LA ROCHE | 2012-11-21 | — | — | CN | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-113512002-B | Pyrazole amide compound containing azo structure, and preparation and application thereof | 华东理工大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-4166539-B1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | PFIZER (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-115536586-B | Pyrazole amide compound as well as preparation method and application thereof | 华东理工大学 | 2024-08-09 | — | — | CN | disclosed |
| CN-114681443-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2024-05-10 | — | — | CN | disclosed |
| EP-0695748-A1 | Tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-02-07 | — | — | EP | disclosed |
| US-5264448-A | Thioamides, oxazole ring, insecticides, miticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| US-5206259-A | Insecticides, acaricides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-04-27 | — | — | US | disclosed |
| US-4968805-A | Pyrazole derivatives and insecticidal fungicidal and miticidal compositions thereof | MITSUBISHI KASEI CORPORATION (JP) | 1990-11-06 | — | — | US | disclosed |
| EP-0394043-A1 | An amide compound and its production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0329020-A1 | Pyrazole derivatives, processes for their manufacture and insecticidal, miticidal and fungicidal compositions containg the derivatives as active ingredients | MITSUBISHI KASEI CORPORATION (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | KDM4E 1904/4885SMN1; SMN2 1912/4885LMNA 2551/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KDM4E 1393/4885SMN1; SMN2 4664/4885LMNA 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.